Valuation: Monopar Therapeutics Inc.

Market Cap 720M 625M 580M 535M 1.01B 68.7B 1.03B 6.87B 2.69B 34.12B 2.7B 2.64B 115B P/E 2026 *
-46.6x
P/E 2027 * -31x
Enterprise Value 601M 522M 485M 447M 842M 57.38B 857M 5.74B 2.25B 28.5B 2.26B 2.21B 95.84B EV / Sales 2026 *
-
EV / Sales 2027 * 38.3x
Free-Float
76.58%
Yield 2026 *
-
Yield 2027 * -
1 day+5.38%
1 week+7.36%
Current month+22.56%
1 month+22.56%
3 months+117.60%
6 months+87.94%
Current year+73.78%
1 week 103
Extreme 103
113.5
1 month 88.33
Extreme 88.33
116.64
Current year 50.07
Extreme 50.07
116.64
1 year 29.18
Extreme 29.18
116.64
3 years 1.37
Extreme 1.3695
116.64
5 years 1.37
Extreme 1.3695
116.64
10 years 1.37
Extreme 1.3695
240
Manager TitleAgeSince
Chief Executive Officer 42 01/12/2014
Director of Finance/CFO 54 03/03/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 42 01/12/2014
Chairman 73 01/12/2014
Director/Board Member 84 01/04/2017
Date Insider Type Main position Quantity % Market Cap.
30/6/26 Fiscal year

Chief Financial Officer

2,963 0.0442%
30/6/26 Fiscal year

Chief Operating Officer

12,817 0.1913%
30/6/26 Fiscal year

Founder

29,830 0.4453%
Change 5-day change 1-year change 3-year change Capi.($)
+5.38%+7.36%+166.01%+2,962.89% 720M
-0.80%+5.16%-0.70%+12.87% 48.95B
-4.42%+14.68%+24.12%+6.25% 40.75B
+4.21%-0.01%+409.90%+619.01% 38.46B
-1.76%-1.77%+7.02%+49.85% 36.38B
+5.56%+11.70%+11.64%+51.50% 28.45B
-1.51%-1.59% - - 16.62B
-1.16%-4.51%+32.14%+128.50% 16.33B
-6.64%-3.11%-9.08%-34.36% 13.65B
-0.06%+3.75%+3.81%+9.62% 13.56B
Average -0.06%+5.01%+71.65%+422.90% 25.39B
Weighted average by Cap. -0.23%+7.17%+75.34%+134.31%

Financials

2026 *2027 *
Net sales - 15.84M 13.76M 12.78M 11.78M 22.2M 1.51B 22.6M 151M 59.23M 751M 59.49M 58.18M 2.53B
Net income -20.16M -17.51M -16.26M -15M -28.25M -1.92B -28.76M -193M -75.38M -956M -75.71M -74.05M -3.21B -35.74M -31.04M -28.83M -26.58M -50.08M -3.41B -50.98M -341M -134M -1.69B -134M -131M -5.7B
Net Debt -119M -103M -95.63M -88.2M -166M -11.32B -169M -1.13B -443M -5.62B -445M -436M -18.91B -112M -97.58M -90.61M -83.57M -157M -10.72B -160M -1.07B -420M -5.33B -422M -413M -17.91B
Logo Monopar Therapeutics Inc.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Employees
22
Date Price Change Volume
31/07/26 USD 113.48 +5.64% 141,255
29/07/26 USD 107.43 -1.53% 357,181
28/07/26 USD 109.09 -1.12% 528,971
27/07/26 USD 110.33 +0.42% 339,767
24/07/26 USD 109.87 +3.95% 229,818
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
107.42USD
Average target price
116.85USD
Spread / Average Target
+8.77%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNPR Stock